Datapoint: GSK Scores Nasal Polyps Approval for Nucala

The FDA on July 29 approved GlaxoSmithKline’s Nucala for the treatment of chronic rhinosinusitis with nasal polyps, making it the first IL-5 inhibitor in its class. The biologic will have to face off against Sanofi and Regeneron’s Dupixent, which was approved for nasal polyps in 2019. Under the pharmacy benefit, Dupixent holds preferred status (with utilization management restrictions applied in most cases) for 38% of all covered lives. Overall, it holds covered or better status for 73% of lives.

SOURCE: MMIT Analytics, as of 8/2/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 30

Datapoint: Exchanges See 4.6 Million Sign-Ups So Far

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 29

Datapoint: Could Georgia Expand Medicaid?

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
November 28

Datapoint: Froedtert Health Set to Acquire Wisconsin Insurer

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today